IGF2BP2 enhances LincRNA01116 stability via m6 A: A potential biomarker and therapeutic target for patients with pre-eclampsia

J Cell Biochem. 2023 Feb;124(2):239-253. doi: 10.1002/jcb.30358. Epub 2022 Dec 20.

Abstract

Pre-eclampsia (PE) is a serious complication in pregnant women characterized by failure of placental remodeling and is one of the primary causes of changes in the placental structure and function. The aberrant expression of long noncoding RNA is associated with the occurrence and progression of PE. This study found that linc01116 expression was significantly downregulated in PE patients and was related to poor uterine spiral artery remodeling. Knockdown of linc01116 remarkably decreased the angiogenesis of trophoblast cells in vitro and in vivo. Mechanistically, IGF2BP2 regulated linc01116 RNA stability via m6 A methylation. Bioinformatics and other experiments further revealed that linc01116 upregulates AAMP expression by adsorbing miR-210-3p in trophoblast cells. In conclusion, this study revealed the critical role of linc01116 in regulating trophoblast angiogenesis. Furthermore, the study provides new clues for detecting placental pathology in PE.

Keywords: IGF2BP2; Linc01116; N6-methyladenosine; angiogenesis; pre-eclampsia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / metabolism
  • Cell Movement / genetics
  • Cell Proliferation / genetics
  • Female
  • Humans
  • MicroRNAs* / genetics
  • Placenta / metabolism
  • Pre-Eclampsia* / genetics
  • Pregnancy
  • RNA, Long Noncoding* / genetics
  • RNA-Binding Proteins / metabolism
  • Trophoblasts / metabolism

Substances

  • MicroRNAs
  • Biomarkers
  • RNA, Long Noncoding
  • IGF2BP2 protein, human
  • RNA-Binding Proteins